Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Perioperative durvalumab ± tremelimumab plus neoadjuvant enfortumab vedotin in cisplatin-ineligible MIBC: phase 3 VOLGA (NCT04960709)

Exploratory Signatera Genome ctDNA results from the durvalumab plus enfortumab vedotin arm of phase 3 VOLGA (NCT04960709), presented by Thomas Powles at ESMO Congress 2026 (Presidential Symposium I, LBA2, October 24, 2026), covered 112 patients with matched evaluable samples at baseline and before cystectomy as of July 2026: 87 of 112 (78%) were ctDNA-positive at baseline, 52 of those 87 (60%) cleared ctDNA before cystectomy, 76 of 112 (68%) were ctDNA-negative before cystectomy, and 24-month event-free survival was 91% if persistently negative, 81% after clearance, and 55% if persistently positive; the New England Journal of Medicine report of the trial does not include these ctDNA results.

New England Journal of MedicineDOI 10.1056/NEJMoa2608323